-
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial
First HER2 directed therapy to show an improvement in overall survival for previously-treated metastatic gastric cancer with a 41% reduction in the risk of death versus chemotherapy Breakthrough Therapy Designation recently granted in the U.S. for ENHERTU in this setting Detailed results from the positive pivotal randomized, controlled phase 2 DESTINY-Gastric01 trial showed Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in objective response rate (ORR) and overall survival (OS), a key secondary endpoint, versus chemotherapy. The trial evaluated patients with HER2 positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma that had progressed following two or…
-
ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial
Results from the phase 2 DESTINY-CRC01 trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful activity in patients with HER2 positive unresectable and/or metastatic colorectal cancer who received at least two prior lines of standard treatment. These results were presented today at the 2020 American Society of Clinical Oncology Virtual Scientific Program (#ASCO20). Colorectal cancer is the third most common cancer and second most common cause of cancer death worldwide. There are currently no medicines approved to specifically treat HER2 positive colorectal cancer, which affects approximately two to five percent of patients with colorectal cancer.[ii] The primary endpoint of confirmed objective response rate…
-
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Breakthrough Therapy Designation recently granted in the U.S. in this setting Results from the ongoing phase 2 DESTINY-Lung01 trial showed Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) achieved a clinically meaningful tumor response in patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC) whose disease had progressed following one or more systemic therapies. These results were presented today at the 2020 American Society of Clinical Oncology Virtual Scientific Program (#ASCO20). Lung cancer is the leading cause of cancer death among both men and…
